PTC Therapeutics (PTCT) director receives new stock and option awards

Rhea-AI Filing Summary

PTC Therapeutics director Jessica Caroline Chutter received new equity awards. On March 24, 2026, she was granted stock options for 3,475 and 2,896 shares of common stock at an exercise price of $64.54 per share, expiring on March 23, 2036.

She also received 4,000 restricted stock units that vest in three equal annual installments starting March 24, 2027, and 3,333 restricted stock units that vest with 1,000 shares on June 2, 2026 and 2,333 shares on January 2, 2027. All transactions reflect compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary 10b5-1

4 transactions reported

Mixed 4 txns

Insider Chutter Jessica Caroline

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,475	$0.00	--
Grant/Award	Stock Option (Right to Buy)	2,896	$0.00	--
Grant/Award	Common Stock	4,000	$0.00	--
Grant/Award	Common Stock	3,333	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,475 shares (Direct); Common Stock — 4,000 shares (Direct)

Footnotes (1)

1. Restricted stock units granted on March 24, 2026 that vest in three equal annual installments, commencing on March 24, 2027. Restricted stock units granted on March 24, 2026 that vest with respect to 1,000 shares underlying such restricted stock units on June 2, 2026, and with respect to the remaining 2,333 shares on January 2, 2027. This option was granted on March 24, 2026 and vests over 36 equal monthly installments, commencing on April 24, 2026. This option was granted on March 24, 2026 and vests over 10 equal monthly installments, commencing on April 2, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chutter Jessica Caroline

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		A		4,000(1)	A	$0	4,000	D
Common Stock	03/24/2026		A		3,333(2)	A	$0	7,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$64.54	03/24/2026		A		3,475		(3)	03/23/2036	Common Stock	3,475	$0	3,475	D
Stock Option (Right to Buy)	$64.54	03/24/2026		A		2,896		(4)	03/23/2036	Common Stock	2,896	$0	2,896	D

Explanation of Responses:

1. Restricted stock units granted on March 24, 2026 that vest in three equal annual installments, commencing on March 24, 2027.

2. Restricted stock units granted on March 24, 2026 that vest with respect to 1,000 shares underlying such restricted stock units on June 2, 2026, and with respect to the remaining 2,333 shares on January 2, 2027.

3. This option was granted on March 24, 2026 and vests over 36 equal monthly installments, commencing on April 24, 2026.

4. This option was granted on March 24, 2026 and vests over 10 equal monthly installments, commencing on April 2, 2026.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PTC Therapeutics (PTCT) report for Jessica Caroline Chutter?

Jessica Caroline Chutter received equity awards, not open-market trades. She was granted stock options over 3,475 and 2,896 shares and restricted stock units for 4,000 and 3,333 shares of PTC Therapeutics common stock as part of her director compensation.

Were the PTC Therapeutics (PTCT) transactions insider buys or sells?

The transactions are classified as grant or award acquisitions, not market buys or sells. All entries use transaction code A, indicating compensation-related grants of stock options and restricted stock units to director Jessica Caroline Chutter, rather than discretionary trading activity.

What are the key terms of Jessica Caroline Chutter’s stock options at PTC Therapeutics (PTCT)?

She received two stock option grants covering 3,475 and 2,896 shares at an exercise price of $64.54 per share. Both options were granted on March 24, 2026 and are scheduled to expire on March 23, 2036, with monthly vesting beginning in April 2026.

How do the restricted stock units for PTC Therapeutics (PTCT) director vest over time?

One grant of 4,000 restricted stock units vests in three equal annual installments starting March 24, 2027. Another grant of 3,333 units vests with 1,000 shares on June 2, 2026 and the remaining 2,333 shares on January 2, 2027, subject to continued service.

How many PTC Therapeutics (PTCT) shares are covered by the new equity awards?

The awards cover multiple components: stock options over 3,475 and 2,896 shares, plus restricted stock units for 4,000 and 3,333 shares. Each component has its own vesting schedule and, for options, a $64.54 exercise price and March 23, 2036 expiration date.